Literature DB >> 10619267

A comparison of melanin bleaching and azure blue counterstaining in the immunohistochemical diagnosis of malignant melanoma.

C J Kligora1, K P Fair, M S Clem, J W Patterson.   

Abstract

Distinguishing heavily pigmented melanocytes from melanophages on routine hematoxylin and eosin slides can be difficult. Melanin bleaching with potassium permanganate solution is a traditional means of removing melanin from tissues and can be used before immunohistochemical staining to remove any pigment that might be confused with the brown chromogen diaminobenzidine. Azure B stains melanin granules green-blue, easily contrasts with diaminobenzidine, and may be used as a counterstain on unbleached sections after immunohistochemical staining. To our knowledge, studies comparing melanin bleaching with azure B counterstaining in the immunohistochemical evaluation of malignant melanomas have not been performed. Paraffin sections from 33 heavily pigmented malignant melanomas were bleached with a 3.0-g/L potassium permanganate solution, immunohistochemically stained for S-100 and HMB-45, and counterstained with hematoxylin. Unbleached sections were similarly stained for S-100 and HMB-45 and counterstained with azure B. To establish optimal permanganate concentrations, a variable number of sections were bleached with lower permanganate concentrations ranging from 0.125 to 2.5 g/L. S-100 antigenicity was preserved at all permanganate concentrations, whereas HMB-45 antigenicity was abolished at concentrations of 0.5 g/L and greater. At permanganate concentrations from 0.125 to 0.5 g/L, both antigenicities were preserved; however, melanin was incompletely removed. Complications of bleaching included tissue damage and loss of cytologic detail. Positive immunohistochemical staining was observed in azure B counterstained sections. Azure B stained melanin greenblue and was easily distinguished from the brown diaminobenzidine chromogen, regardless of the antibody tested. Neither tissue damage nor loss of cytologic detail was observed. We conclude that the use of azure B counterstaining is superior to permanganate bleaching in the histologic evaluation of heavily pigmented cutaneous malignant melanomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619267

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  A melanin-bleaching methodology for molecular and histopathological analysis of formalin-fixed paraffin-embedded tissue.

Authors:  Joon-Yong Chung; Jiyeon Choi; John D Sears; Kris Ylaya; Candice Perry; Chel H Choi; Seung-Mo Hong; Hanbyoul Cho; Kevin M Brown; Stephen M Hewitt
Journal:  Lab Invest       Date:  2016-08-22       Impact factor: 5.662

2.  Expression of varicella-zoster virus immediate-early regulatory protein IE63 in neurons of latently infected human sensory ganglia.

Authors:  Leigh Zerboni; Raymond A Sobel; Vasavi Ramachandran; Jaya Rajamani; William Ruyechan; Allison Abendroth; Ann Arvin
Journal:  J Virol       Date:  2010-01-27       Impact factor: 5.103

3.  Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma.

Authors:  A Curioni-Fontecedro; R Pitocco; N L Schoenewolf; D Holzmann; D Soldini; R Dummer; S Calvieri; H Moch; D Mihic-Probst; A Fitsche
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

4.  Study of melanin bleaching after immunohistochemistry of melanin-containing tissues.

Authors:  Hongwu Shen; Wenqiao Wu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-04

5.  Effective melanin depigmentation of human and murine ocular tissues: an improved method for paraffin and frozen sections.

Authors:  Caroline Manicam; Susanne Pitz; Christoph Brochhausen; Franz H Grus; Norbert Pfeiffer; Adrian Gericke
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

6.  High-contrast enzymatic immunohistochemistry of pigmented tissues.

Authors:  Sara M Duncan; Gail M Seigel
Journal:  J Biol Methods       Date:  2016-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.